<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/22/2022 4:20:26 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 1bc33852-1d0a-41bc-ac1c-6edd40d073c2 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:krbp="http://www.kiromic.com/20221116" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityCentralIndexKey" id="Tc_elSYbYVudESeZfN5MeiaLQ_2_1">0001792581</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:AmendmentFlag" id="Tc_Ipc5hUF7tE-L066s3izd2Q_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="krbp-20221116.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001792581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_13e487b5_9211_4680_8d52_05eee5050f2d"></a><a id="BigHand_Transcription"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:DocumentType" id="Narr_zAw46KjTLkmj1rPFQ_eXKA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_nimtySnarkObHcEtR4J-0w"><span style="font-size:11pt;">November 16, 2022</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityRegistrantName" id="Narr_RJ64fWCU-kmPc64xIG-AWg"><b style="font-weight:bold;">KIROMIC BIOPHARMA, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_9aa7816e_96b8_41a5_a781_666415155525"></a><a id="Tc_RSBx7MjN9Eer29ayHVLjmw_2_0"></a><a id="Tc_nXIgbf1RiEeWE9o3xuvcHQ_2_2"></a><a id="Tc_nf6Q1lloakS8Uye-ieGQ9Q_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.99%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_-EM0KgnpXUS82zZYLmDDyg_1_0"><b style="font-size:11pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.82%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityFileNumber" id="Tc_fUhvEot0MkCXTBbg_tthBg_1_2"><b style="font-size:11pt;font-weight:bold;">001-39619</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityTaxIdentificationNumber" id="Tc_DnIDDd6bSECAbFLtTntZ-w_1_4"><b style="font-size:11pt;font-weight:bold;">46-4762913</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(State or other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">of incorporation)</p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Commission</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityAddressAddressLine1" id="Narr_XjiLDLhLQUWhYICE9UUxNw"><b style="font-size:11pt;font-weight:bold;">7707 Fannin Street</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityAddressAddressLine2" id="Narr_D3DK-88HXEqR6G2GbQ1lBQ"><b style="font-size:11pt;font-weight:bold;">Suite 140</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityAddressCityOrTown" id="Narr_BEc4YtdJzUia143sarKcmA"><b style="font-size:11pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityAddressStateOrProvince" id="Narr_gQs3vvBWIU2dwKAde96Jrw"><b style="font-size:11pt;font-weight:bold;">TX</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:EntityAddressPostalZipCode" id="Narr_1kJLdBnc80OutRBKBYrGGg"><b style="font-size:11pt;font-weight:bold;">77054</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Registrant&#8217;s telephone number, including area code&#160;</span><b style="font-size:11pt;font-weight:bold;background:#ffffff;">(</b><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:CityAreaCode" id="Narr_4fH933VjlUKwhWH63k2Jow"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">832</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;background:#ffffff;">)&#160;</b><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:LocalPhoneNumber" id="Narr_ZQ0HpfZUyESZmqJYG9Be7g"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">968-4888</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:-24pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_fa70823f_c6f1_4e89_9c9a_a13603f06cad"></a><a id="Tc_s844OBB580WDrtXBtUAd8Q_1_1"></a><a id="Tc_5NgT7pKFr0O2U9Z4fQY6-g_3_1"></a><a id="Tc_XmYaZWwqkU6UugamhJ3iMA_5_1"></a><a id="Tc_oeal5QIxO0Gb1sLWMcb-QA_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.99%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_s5zJsfFxUEO3eITN688hIA_1_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_NP-MTWwSdU6GqvoKKb_lLw_3_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_4DHz_nSk0UeAYvL5WNde6g_5_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_z094UUJnZUugQvLo9dQ6WA_7_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 18pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_5a1855d2_097f_4c3b_a710_dc60a883cfc8"></a><a id="Tc_LiClHGkGSUayQKDTQHyCGA_1_0"></a><a id="Tc_wu3y9_HYJEG6y0R0Iasa-w_1_2"></a><a id="Tc_WU9JlqD6TUWnI2DFoI9hOA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.99%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:Security12bTitle" id="Tc_1e5j1tAhJky9b803B0Q6Mg_2_0"><span style="font-size:11pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.94%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" name="dei:TradingSymbol" id="Tc_c9dYmgtoJU-krvcH-LrRUw_2_2"><span style="font-size:11pt;">KRBP</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_uYrGZISZsUGI16pKfhCevw_2_4"><span style="font-size:11pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_v7p8chH1wkyveJCazrvoqg"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_11_16_2022_To_11_16_2022_--tiIoHN5EWruAqNPGEXbQ" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_7krMhI5NpEe_Tz6YHJv8oA"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:23.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_6f27839a_9d72_4937_ae4a_99a451b72cf8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:104.8%;background:#ffffff;"><tr><td style="vertical-align:top;width:13.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;5.02</b></p></td><td style="vertical-align:top;width:86.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;background:#ffffff;margin:12pt -27pt 0pt 0pt;">On November 16, 2022, Frank Tirelli informed the Board of Directors (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</span>&#8221;) of Kiromic BioPharma, Inc. (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;) that he was resigning his position as a director of the Company, effective immediately. Mr. Tirelli also ceased to be a member of the Audit Committee, and the Nominating and Corporate Governance Committee of the Board, effective immediately. &#160;Mr. Tirelli&#8217;s resignation did not involve a disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt -27pt 0pt 0pt;">As a result of Mr. Tirelli&#8217; resignation, the Company will no longer be in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Company&#8217;s Audit Committee be comprised of three independent directors. As of November 16, 2022, the Company&#8217;s Audit Committee was comprised of two independent directors. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Listing Rule 5605(c)(2)(A). </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt -27pt 0pt 0pt;">The Nominating and Corporate Governance Committee of the Board is seeking and will be reviewing qualified candidates to fill the vacant board seat. The Company expects to be compliant with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A) by the end of the cure period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt -27pt 0pt 0pt;"><span style="font-size:11pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:48.25pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b6e45bf2_2d93_4bb9_9af5_de1baed87cb1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Kiromic BioPharma, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Date: November 22, 2022</p></td><td colspan="2" style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.8%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Daniel Clark</span></p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Daniel Clark</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:24pt;"><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:24pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:24pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:14.4pt;min-height:57.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "krbp-20221116x8k.htm", "description": "8-K", "secsgml_size_bytes": 35181}]
{"company-data": {"conformed-name": "Kiromic Biopharma, Inc.", "cik": "0001792581", "assigned-sic": "2836", "irs-number": "464762913", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39619", "film-number": "221410255"}, "business-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054", "phone": "832-968-4888"}, "mail-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054"}, "former-company": {"former-conformed-name": "Kiromic, Inc.", "date-changed": "20191029"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
​
FORM
8-K
​
CURRENT REPORT
​
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported):
November 16, 2022
​
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
​
Delaware
001-39619
46-4762913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
7707 Fannin Street
,
Suite 140
Houston
,
TX
,
77054
(Address of principal executive offices) (Zip Code)
​
Registrant's telephone number, including area code
(
832
)
968-4888
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value
KRBP
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
​
Emerging growth company
☒
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
​
​
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
On November 16, 2022, Frank Tirelli informed the Board of Directors (the "
Board
") of Kiromic BioPharma, Inc. (the "
Company
") that he was resigning his position as a director of the Company, effective immediately. Mr. Tirelli also ceased to be a member of the Audit Committee, and the Nominating and Corporate Governance Committee of the Board, effective immediately.  Mr. Tirelli's resignation did not involve a disagreement with the Company on any matter relating to the Company's operations, policies or practices.
As a result of Mr. Tirelli' resignation, the Company will no longer be in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Company's Audit Committee be comprised of three independent directors. As of November 16, 2022, the Company's Audit Committee was comprised of two independent directors. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Listing Rule 5605(c)(2)(A).
The Nominating and Corporate Governance Committee of the Board is seeking and will be reviewing qualified candidates to fill the vacant board seat. The Company expects to be compliant with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A) by the end of the cure period.
​
2
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
Kiromic BioPharma, Inc.
Date: November 22, 2022
By:
/s/ Daniel Clark
Daniel Clark
Chief Financial Officer
​
​
​
​
​
​
​
​
3